Literature DB >> 9607891

Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.

T F Zaher1.   

Abstract

PURPOSE: A study comparing intracorporeal injection of prostaglandin E1 (one-drug solution) and papaverine plus prostaglandin E1 (2-drug solution) for treatment of impotence.
MATERIALS AND METHODS: A total of 100 impotent patients had intracorporeal injections of the one-drug and 2-drug solution alternatively in 3 sessions. The quality and duration of erections were assessed.
RESULTS: Seventy-five per cent of the patients developed full erection with the 2-drug solution compared to 50% with the one-drug solution. The average duration of erections was 60 minutes and 45 minutes, respectively. The complication rate was higher for the 2-drug solution.
CONCLUSION: Papaverine plus prostaglandin E1 is superior to prostaglandin E1 alone for treatment of impotence, but has a higher rate of complications. Intracavemous injection of vasoactive drugs is a very effective and important way for treatment of impotence. Papaverine plus prostaglandin E1 had been used for treatment of impotence alone or combined. A blind study was done to compare efficiency and complication rates of intracavemous injection of papaverine plus prostaglandin E1 (2-drug solution) with prostaglandin E1 alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607891     DOI: 10.1007/bf02550576

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence.

Authors:  S B Levine; S E Althof; L A Turner; C B Risen; D R Bodner; E D Kursh; M I Resnick
Journal:  J Urol       Date:  1989-01       Impact factor: 7.450

2.  An improved vasoactive drug combination for a pharmacological erection program.

Authors:  A H Bennett; A J Carpenter; J H Barada
Journal:  J Urol       Date:  1991-12       Impact factor: 7.450

Review 3.  How safe is the treatment of impotence with intracavernous autoinjection?

Authors:  M Zentgraf; G Ludwig; M Ziegler
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

4.  Intracavernous injection therapy: analysis of results and complications.

Authors:  M M Lakin; D K Montague; S VanderBrug Medendorp; L Tesar; L R Schover
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

5.  Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery.

Authors:  H Hedlund; K E Andersson
Journal:  J Urol       Date:  1985-12       Impact factor: 7.450

6.  Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence.

Authors:  G S Brindley
Journal:  Br J Psychiatry       Date:  1983-10       Impact factor: 9.319

Review 7.  Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.

Authors:  B von Heyden; C F Donatucci; N Kaula; T F Lue
Journal:  J Urol       Date:  1993-05       Impact factor: 7.450

8.  Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.

Authors:  A Floth; P Schramek
Journal:  J Urol       Date:  1991-01       Impact factor: 7.450

9.  Why do so many people drop out from auto-injection therapy for impotence?

Authors:  S E Althof; L A Turner; S B Levine; C Risen; E Kursh; D Bodner; M Resnick
Journal:  J Sex Marital Ther       Date:  1989

10.  Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.

Authors:  O Shenfeld; J Hanani; A Shalhav; Y Vardi; B Goldwasser
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

  10 in total
  2 in total

1.  Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.

Authors:  Otacilio D Benvindo; Nilberto Rf Nascimento; Claudia F Santos; Manasses C Fonteles; Edilberto R Silveira; Daniel E Uchoa; Adriana R Campos; Karina Ma Cunha; Flavia A Santos; Vietla S Rao
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

Review 2.  Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.

Authors:  Stephen L Archer; Ferrante S Gragasin; Linda Webster; Derek Bochinski; Evangelos D Michelakis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.